The main Henry Meds lawsuit is a federal false-advertising case brought by Eli Lilly in April 2025, accusing the telehealth company of marketing mass-produced compounded tirzepatide as “personalized” treatment and trading on the reputation of Lilly’s FDA-approved drugs Mounjaro and Zepbound. A judge allowed the core claim to move forward in September 2025, and the case is now in discovery in the Northern District of California with no trial date set.
What Eli Lilly Is Claiming
Lilly filed suit against Adonis Health Inc., which does business as Henry Meds, on April 23, 2025 (Case No. 4:25-cv-03536).{1CourtListener. Eli Lilly and Company v. Adonis Health, Inc.} The complaint targets how Henry Meds sold compounded tirzepatide, the active ingredient in Lilly’s obesity drug Zepbound and diabetes drug Mounjaro.
The allegations break into three main pieces. Lilly says Henry Meds falsely advertised its compounded products as “personalized,” “individualized,” and “patient-specific” when the treatments were in fact standardized and mass-produced.{2Bloomberg Law. Eli Lilly Suit Over Personalized Obesity Drugs Gets Go-Ahead} It also alleges Henry Meds improperly referenced Lilly’s clinical trial data and FDA-approved drug names on its website to sell unapproved compounded versions.{} And it points to Henry Meds’ sale of tirzepatide in oral pill form, a delivery method the FDA has never studied or approved.{3NPR. Eli Lilly Sues Companies Selling Alternative Versions of Its Weight Loss Drug}
Lilly argues these practices put patients at risk because compounded drugs skip the safety and efficacy review required for FDA approval. It also says the marketing causes “irreparable harm” to its brands by promising outcomes that copycat compounded products cannot deliver.
The September 2025 Ruling
On September 24, 2025, Judge Jon S. Tigar ruled on Henry Meds’ motion to dismiss. He let the central claim proceed, finding Lilly had “plausibly alleged” that the “personalized” marketing was literally false because the compounded products were standardized rather than tailored to individual patients.{2Bloomberg Law. Eli Lilly Suit Over Personalized Obesity Drugs Gets Go-Ahead}
One piece was dismissed. Lilly had also alleged Henry Meds falsely marketed the compounded drugs as “safe and effective,” but the court found Lilly had not shown those statements were actually false, characterizing the argument as a “lack of substantiation” rather than proof of falsity. Lilly was given leave to amend on that issue.{1CourtListener. Eli Lilly and Company v. Adonis Health, Inc.}
Where the Case Stands
The lawsuit is in active discovery. In January 2026, Henry Meds filed a motion for a protective order, which the court granted in March, indicating disputes over what information the parties must exchange. On June 16, 2026, the court referred the matter to a magistrate judge to oversee discovery.{1CourtListener. Eli Lilly and Company v. Adonis Health, Inc.} No trial date has been set, and legal observers expect the case to take years to resolve.
Henry Meds continues to operate during the litigation. Its defense reportedly rests on the 503A patient-specific compounding framework and the clinical judgment of individual prescribers.{4Forbes. Henry Meds Review}
Why Lilly Sued Now
The legality of compounded tirzepatide turns on the FDA’s drug shortage list. Federal law lets compounding pharmacies produce versions of drugs in shortage, but once a shortage is resolved, compounding “essentially a copy” of an FDA-approved product is generally prohibited.
Tirzepatide was on the shortage list from December 2022 until the FDA declared the shortage resolved on December 19, 2024.{5FDA. FDA Memorandum on Tirzepatide Shortage Resolution} Compounders were given short wind-down periods that ended in early 2025.{6FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize} Lilly filed its lawsuits shortly after those deadlines passed. Semaglutide followed a similar path off the shortage list in February 2025.
The FDA has also stepped up its own enforcement. In March 2026, the agency sent 30 warning letters to telehealth companies over illegal marketing of compounded GLP-1 drugs, targeting firms whose ads implied their products were equivalent to brand-name medications or obscured where the drugs came from.{7FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s}
Lilly’s Other Telehealth and Pharmacy Suits
The Henry Meds case is part of a wider Lilly campaign. On the same day it sued Henry Meds, the company also filed suits in the Northern District of California against three other telehealth platforms: Mochi Health, Fella Health, and Willow Health Services.{3NPR. Eli Lilly Sues Companies Selling Alternative Versions of Its Weight Loss Drug} Earlier in April 2025, Lilly had sued Strive Pharmacy in Delaware and Empower Pharmacy in New Jersey.
The claims vary. Against Mochi and Fella, Lilly added allegations of the “unlawful corporate practice of medicine,” accusing the companies of improperly controlling prescribing and formulation decisions.{3NPR. Eli Lilly Sues Companies Selling Alternative Versions of Its Weight Loss Drug} The Henry Meds case is more narrowly a false-advertising claim under the Lanham Act.
Results in the parallel cases have been mixed. In April 2026, a judge allowed Lilly’s false advertising and unfair competition claims against Mochi Health to proceed while dismissing a civil conspiracy claim.{8Courthouse News. Eli Lilly vs. Mochi Health Order} The Strive Pharmacy case was dismissed in October 2025 on jurisdictional grounds, with the court finding that operating a national website was not enough to establish personal jurisdiction in Delaware.{9U.S. District Court for the District of Delaware. Eli Lilly and Company v. Strive Pharmacy, Opinion} Part of the Empower Pharmacy suit was dismissed in April 2026, with some claims allowed to continue.{10Endpoints News. Court Dismisses Part of Lilly Lawsuit Against Empower, Some Claims Can Proceed}
Consumer Complaints and Possible Arbitration Claims
Separate from the Lilly suit, Henry Meds has drawn consumer scrutiny. Its Better Business Bureau profile lists 212 complaints over the past three years, with 89 closed in the most recent 12 months. The company is not BBB accredited.{11BBB. Henry Meds BBB Complaints} The most common issues involve product delivery (83 complaints), service failures (53), and billing disputes (23).
Consumers describe a recurring pattern: difficulty canceling subscriptions, charges after cancellation requests, and trouble reaching the company. One customer said they were charged monthly from July 2025 through March 2026 despite terminating service in June 2025. Another said they were charged $297 after requesting cancellation two weeks earlier.{12BBB. Henry Meds BBB Complaints, Page 3} In its BBB responses, Henry Meds has said “prescription products are considered final sale” and that pharmacy-dispensed medications are generally ineligible for return or refund.
In September 2025, the National Consumers League petitioned the Federal Trade Commission to investigate Henry Meds and other telehealth platforms for deceptive advertising of compounded GLP-1 drugs. The petition cited specific Henry Meds television spots and social media posts, alleging incomplete risk disclaimers, misleading testimonials, and deceptive marketing of “personalized” weight-loss treatments.{13National Consumers League. NCL Petition to the FTC on Deceptive Advertising of Compounded GLP-1 Drugs}
Law firms Zimmerman Reed and Tycko & Zavareei have publicly announced investigations into potential consumer claims against Henry Meds for deceptive marketing of compounded GLP-1 drugs. No class action or mass arbitration has been filed. The firms are signing up consumers who purchased compounded GLP-1 products to pursue arbitration claims for financial recovery. If you bought compounded semaglutide, tirzepatide, or liraglutide from Henry Meds and want to preserve a possible claim, keep your order records, cancellation requests, billing statements, and copies of the marketing you saw.